Rhopaladin B exhibited inhibitory activity against CDK4 (cyclin-dependent kinase 4) and c-erbB-2 kinase, with IC50 values of 12.5 and 7.4 μg/mL, respectively, indicating potential significant cytotoxicity to human tumor cells [98]. This evidence concerns the gene CDK4 and neoplasm.